Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:CMND

Clearmind Medicine Q2 2026 Earnings Report

Clearmind Medicine logo
$0.82 +0.01 (+1.44%)
As of 11:15 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings History

Clearmind Medicine EPS Results

Actual EPS
-$6.78
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Clearmind Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Clearmind Medicine Announcement Details

Quarter
Q2 2026
Date
6/15/2026
Time
After Market Closes
Conference Call Date
Monday, June 15, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Clearmind Medicine's Q2 2026 Press ReleasePress Release
(6-K)
Clearmind Medicine's Q2 2026 Interim reportInterim report

Clearmind Medicine Earnings Headlines

Clearmind Medicine Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
September 24 at 1:18 PM  |  marketscreener.comM
NeuroThera Labs Inc. And Clearmind Medicine Inc. Highlight Enhancement Of U.S. Patent Portfolio Through Collaboration Covering LSD, Ketamine And Ibogaine Combinations
September 23 at 1:43 PM  |  marketscreener.comM
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
September 25 at 1:00 AM  |  Stansberry Research (Ad)
Clearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-Acylethanolamines
September 23 at 8:11 AM  |  quiverquant.comQ
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
September 23 at 7:57 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367404/0/en/clearmind-enhances-u-s-ip-presence-with-publication-of-three-patent-applications-covering-lsd-ketamine-and-ibogaine-combinations.html
Clearmind Medicine Testifies at FDA Psychedelic Hearing on Patient Access and MEAI Clinical Trial Insights
September 17, 2026  |  quiverquant.comQ
See More Clearmind Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearmind Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearmind Medicine and other key companies, straight to your email.

About Clearmind Medicine

Clearmind Medicine (NASDAQ:CMND) is a biotechnology company focused on developing psychedelic-derived therapeutics for behavioral and mental health disorders. Its research programs are designed to address conditions with significant unmet medical needs, including alcohol use disorder and binge-related behaviors.

The company’s pipeline includes investigational compounds based on novel psychedelic molecules, including 5-methoxy-2-aminoindane (MEAI). Clearmind is studying these compounds for their potential to reduce harmful consumption patterns and support improved mental health outcomes. Its activities include preclinical research, drug discovery and the advancement of candidates toward clinical development.

Clearmind Medicine is incorporated in Canada and has conducted research and development activities internationally, including in Israel. The company’s programs remain investigational, and its product candidates have not been approved for commercial sale by regulatory authorities.

View Clearmind Medicine Profile
Earnings Tools